PMID- 36054746
OWN - NLM
STAT- MEDLINE
DCOM- 20221021
LR  - 20221116
IS  - 1878-0261 (Electronic)
IS  - 1574-7891 (Print)
IS  - 1574-7891 (Linking)
VI  - 16
IP  - 20
DP  - 2022 Oct
TI  - IL-7 is expressed in malignant mesothelioma and has a prognostic value.
PG  - 3606-3619
LID - 10.1002/1878-0261.13310 [doi]
AB  - Malignant pleural mesothelioma (MPM) is an aggressive cancer mainly related to 
      asbestos exposure. Despite recent therapeutic advances, notably immunotherapies, 
      the benefit remains limited and restricted to a small percentage of patients. 
      Thus, a better understanding of the disease is needed to identify new therapeutic 
      strategies. Recently, interleukin 7 receptor (IL-7R) has been described as being 
      expressed by MPM cells and associated with poorer patient survival. Thus, the aim 
      of this work was to study the IL-7R/IL-7 pathway in MPM using patient samples. We 
      found that, although more than 40% of MPM cells expressed IL-7R, IL-7 had no 
      effect on their intracellular signaling. Accordingly, the addition of IL-7 to the 
      culture medium did not affect MPM cell growth. Using The Cancer Genome Atlas 
      (TCGA) database, we showed that high IL7 gene expression in MPM tumors was 
      associated with a higher overall patient survival and an induction of genes 
      involved in the immune response. In pleural effusions (PEs), we found that IL-7 
      concentration was not a good diagnostic biomarker. However, we observed that high 
      IL-7 levels in PEs were associated with shorter survival of MPM patients, but not 
      of lung cancer patients. The prognostic value of IL-7 was also conserved when 
      only patients with epithelioid mesothelioma, the most common histological type of 
      MPM, were analyzed. Taken together, our study suggests that, although the 
      IL-7R/IL-7 signaling pathway is not functional in MPM cells, IL-7 expression in 
      PEs may have prognostic value in MPM patients.
CI  - (c) 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on 
      behalf of Federation of European Biochemical Societies.
FAU - Mai, Hoa-Le
AU  - Mai HL
AD  - CHU Nantes, INSERM, Center for Research in Transplantation and Translational 
      Immunology, UMR 1064, Nantes Universite, Nantes, France.
AD  - Immunology Graft Oncology, Labex IGO, Nantes, France.
FAU - Deshayes, Sophie
AU  - Deshayes S
AD  - Immunology Graft Oncology, Labex IGO, Nantes, France.
AD  - Nantes Universite, Inserm UMR 1307, CNRS UMR 6075, Universite d'Angers, CRCI2NA, 
      Nantes, France.
FAU - Nguyen, Thi-Van-Ha
AU  - Nguyen TV
AD  - CHU Nantes, INSERM, Center for Research in Transplantation and Translational 
      Immunology, UMR 1064, Nantes Universite, Nantes, France.
AD  - Immunology Graft Oncology, Labex IGO, Nantes, France.
FAU - Dehame, Virginie
AU  - Dehame V
AD  - Immunology Graft Oncology, Labex IGO, Nantes, France.
AD  - Nantes Universite, Inserm UMR 1307, CNRS UMR 6075, Universite d'Angers, CRCI2NA, 
      Nantes, France.
FAU - Chene, Anne-Laure
AU  - Chene AL
AD  - Nantes Universite, Inserm UMR 1307, CNRS UMR 6075, Universite d'Angers, CRCI2NA, 
      Nantes, France.
AD  - Service de pneumologie, L'institut du thorax, Hopital Guillaume et Rene Laennec, 
      CHU Nantes, Nantes, France.
FAU - Brouard, Sophie
AU  - Brouard S
AD  - CHU Nantes, INSERM, Center for Research in Transplantation and Translational 
      Immunology, UMR 1064, Nantes Universite, Nantes, France.
AD  - Immunology Graft Oncology, Labex IGO, Nantes, France.
FAU - Blanquart, Christophe
AU  - Blanquart C
AUID- ORCID: 0000-0002-0917-3747
AD  - Immunology Graft Oncology, Labex IGO, Nantes, France.
AD  - Nantes Universite, Inserm UMR 1307, CNRS UMR 6075, Universite d'Angers, CRCI2NA, 
      Nantes, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220910
PL  - United States
TA  - Mol Oncol
JT  - Molecular oncology
JID - 101308230
RN  - 0 (Interleukin-7)
RN  - 1332-21-4 (Asbestos)
RN  - 0 (Receptors, Interleukin-7)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Humans
MH  - *Mesothelioma, Malignant
MH  - *Mesothelioma/genetics/diagnosis
MH  - *Pleural Neoplasms/genetics
MH  - Interleukin-7
MH  - Prognosis
MH  - *Asbestos
MH  - *Lung Neoplasms/pathology
MH  - Receptors, Interleukin-7
MH  - Biomarkers
PMC - PMC9580880
OTO - NOTNLM
OT  - IL-7
OT  - IL-7R
OT  - biomarker
OT  - mesothelioma
OT  - pleural fluids
COIS- The authors declare no conflict of interest.
EDAT- 2022/09/03 06:00
MHDA- 2022/10/22 06:00
PMCR- 2022/10/01
CRDT- 2022/09/02 15:04
PHST- 2022/08/02 00:00 [revised]
PHST- 2022/05/04 00:00 [received]
PHST- 2022/08/07 00:00 [accepted]
PHST- 2022/09/03 06:00 [pubmed]
PHST- 2022/10/22 06:00 [medline]
PHST- 2022/09/02 15:04 [entrez]
PHST- 2022/10/01 00:00 [pmc-release]
AID - MOL213310 [pii]
AID - 10.1002/1878-0261.13310 [doi]
PST - ppublish
SO  - Mol Oncol. 2022 Oct;16(20):3606-3619. doi: 10.1002/1878-0261.13310. Epub 2022 Sep 
      10.